News from NORD

NORD Supports Orphan Drug Tax Credit


 

NORD recently joined 140 other patient advocacy organizations in sending a letter to Congress urging that the Orphan Drug Tax Credit remain in place. The Orphan Drug Tax Credit is one of the incentives in the Orphan Drug Act that have promoted R & D on diagnostics and treatments for people with rare diseases since 1983.

As Congress discusses possible approaches to tax reform, some options would include doing away with the ODTC. However, NORD and its policy partners believe patients with rare diseases would suffer if that were to happen. A 2015 study showed that one-third fewer orphan drugs would be developed if the ODTC did not exist.

Recommended Reading

Foundation Fighting Blindness Opens USH2A Natural History Study
MDedge Family Medicine
PSC Partners Seeking a Cure Surpasses 1,000 Patients in International Registry … and Makes an Unexpected Finding Regarding Misdiagnosis
MDedge Family Medicine
TESS Research Foundation Announces Grant Recipients
MDedge Family Medicine
Vestibular Disorders Association Celebrates Balance Awareness Week
MDedge Family Medicine
Biologic may bring relief for children and adults with XLH syndrome
MDedge Family Medicine
Fever and bilateral ankle pain
MDedge Family Medicine
Nominate a Colleague or Patient for a NORD Rare Impact Award
MDedge Family Medicine
Orphan Drugs Are Not Driving Up the Cost of Health Care, According to New Study
MDedge Family Medicine
NORD Call for Abstracts Reopened
MDedge Family Medicine
NORD Board Chair to Moderate Social Security Administration Forum
MDedge Family Medicine